HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of ondansetron on emesis in the first 24 hours after craniotomy in children.

Abstract
Children undergoing neurosurgical resection are at high risk for postoperative nausea and vomiting. Ondansetron, a selective serotonergic (5-HT3) antagonist, is effective in reducing postoperative vomiting in several high-risk populations. In a prospective, randomized study, we compared the prophylactic use of intravenous ondansetron, 0.15 mg/kg, versus placebo for the prevention of emesis in 60 children, aged 2-18 yr, undergoing craniotomies for resective procedures. Patients with preoperative emesis were excluded from the study. All patients were tracheally extubated at the conclusion of surgery, and each episode of emesis during the first 24 postoperative hours was recorded. For the entire 24-h interval, the incidence of emesis in children who received ondansetron (57%) was not significantly different from that in those who received placebo (66%); however, in the first 8 h, the incidence was 25% (ondansetron) vs 44% (placebo) (P = not significant). In those receiving placebo, there was no difference in emesis between patients undergoing operations above versus below the tentorium. Although our sample size was too small to completely exclude any beneficial effect, ondansetron appears ineffective in preventing postoperative emesis in this patient population.
AuthorsS R Furst, L J Sullivan, S G Soriano, J S McDermott, P D Adelson, M A Rockoff
JournalAnesthesia and analgesia (Anesth Analg) Vol. 83 Issue 2 Pg. 325-8 (Aug 1996) ISSN: 0003-2999 [Print] United States
PMID8694313 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antiemetics
  • Placebos
  • Serotonin Antagonists
  • Ondansetron
Topics
  • Adolescent
  • Antiemetics (administration & dosage, therapeutic use)
  • Brain (surgery)
  • Cerebellum (surgery)
  • Child
  • Child, Preschool
  • Craniotomy (adverse effects)
  • Double-Blind Method
  • Female
  • Humans
  • Incidence
  • Injections, Intravenous
  • Male
  • Nausea (prevention & control)
  • Ondansetron (administration & dosage, therapeutic use)
  • Placebos
  • Postoperative Complications (prevention & control)
  • Prospective Studies
  • Serotonin Antagonists (administration & dosage, therapeutic use)
  • Time Factors
  • Vomiting (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: